	US 12,109,221 B2
	Combination therapy for treating cancer
Ruth Muñoz Risueño, Barcelona (ES); Mari Carmen Lara Castillo, Barcelona (ES); and Amaia Etxabe Alberdi, Barcelona (ES)
Assigned to LEUKOS BIOTECH, S.L., Barcelona (ES); and FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS, Badalona (ES)
Filed by LEUKOS BIOTECH, S.L., Barcelona (ES); and FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS, Badalona (ES)
Filed on Aug. 10, 2022, as Appl. No. 17/818,841.
Application 17/818,841 is a continuation of application No. 16/478,121, granted, now 11,446,321, previously published as PCT/EP2018/050876, filed on Jan. 15, 2018.
Claims priority of application No. 17382015 (EP), filed on Jan. 16, 2017.
Prior Publication US 2023/0122940 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7068 (2006.01); A61K 31/485 (2006.01); A61K 31/55 (2006.01); A61K 31/706 (2006.01); A61P 35/02 (2006.01)

CPC A61K 31/7068 (2013.01) [A61K 31/485 (2013.01); A61K 31/55 (2013.01); A61K 31/706 (2013.01); A61P 35/02 (2018.01)]

15 Claims

1. A synergistic combination for the treatment of a hematological malignancy comprising

(a) an ATC/DDD L01B antimetabolite; and

(b) a type 1A or type 1B HTR serotonin receptor (HTR1A or HTR1B) small molecule antagonist, at a molar ratio of HTR1A or HTR1B small molecule antagonist to ATC/DDD L01B antimetabolite between

(i) 500:1 and 2:1 when the ATC/DDD L01B antimetabolite is a pyrimidine analogue;

(ii) 1000:1 and 5:1 when the ATC/DDD L01B antimetabolite is a purine analogue; or

(iii) 4000:1 to 400:1 when the ATC/DDD L01B antimetabolite is a folic acid analogue;

wherein the synergistic combination comprising the ATC/DDD L01B antimetabolite and the HTR1A or HTR1B small molecule antagonist is capable of synergistically killing hematological malignancy cells expressing HTR1A or HTR1B.